| scholarly article | Q13442814 |
| P50 | author | Daniela Schuster | Q37376677 |
| P2093 | author name string | Anna Vuorinen | |
| Alex Odermatt | |||
| Fabio Bachmann | |||
| Ulrich J Griesser | |||
| Arne Meyer | |||
| Roger Engeli | |||
| P2860 | cites work | Long term hormone therapy for perimenopausal and postmenopausal women | Q24201974 |
| Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3 | Q24318647 | ||
| Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity | Q24321936 | ||
| The Protein Data Bank | Q24515306 | ||
| European guidance for the diagnosis and management of osteoporosis in postmenopausal women | Q24612411 | ||
| Discovery of N-(3-((7H-purin-6-yl)thio)-4-hydroxynaphthalen-1-yl)-sulfonamide derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part III. | Q39033192 | ||
| Structural optimization of 2,5-thiophene amides as highly potent and selective 17β-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis | Q39245972 | ||
| 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate | Q40261817 | ||
| Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption | Q40350036 | ||
| Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships | Q40541359 | ||
| Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function | Q40921086 | ||
| Osteoporosis. Definition and clinical presentation | Q41683513 | ||
| Novel estrone mimetics with high 17beta-HSD1 inhibitory activity | Q43088431 | ||
| Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues | Q44146025 | ||
| Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11β-hydroxysteroid dehydrogenase type 2. | Q44683619 | ||
| Human 17beta-hydroxysteroid dehydrogenase type 2 messenger ribonucleic acid expression and localization in term placenta and in endometrium during the menstrual cycle. | Q50896417 | ||
| Mouse 17 beta-hydroxysteroid dehydrogenase type 2 mRNA is predominantly expressed in hepatocytes and in surface epithelial cells of the gastrointestinal and urinary tracts. | Q50901047 | ||
| Characterization of molecular and catalytic properties of intact and truncated human 17beta-hydroxysteroid dehydrogenase type 2 enzymes: intracellular localization of the wild-type enzyme in the endoplasmic reticulum. | Q52571232 | ||
| Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening. | Q52607792 | ||
| Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1998) | Q54260077 | ||
| Characterization of 17beta-hydroxysteroid dehydrogenase isoenzyme expression in benign and malignant human prostate | Q71019268 | ||
| 17Beta-hydroxysteroid dehydrogenase types 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development | Q77398383 | ||
| 17β-HSD2 inhibitors for the treatment of osteoporosis: Identification of a promising scaffold | Q83144562 | ||
| Synthesis and biological evaluation of phenyl substituted 1H-1,2,4-triazoles as non-steroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 2 | Q83987365 | ||
| Medium- and short-chain dehydrogenase/reductase gene and protein families : the SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes | Q24642281 | ||
| Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy | Q27658290 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q27861111 | ||
| 17Beta-hydroxysteroid dehydrogenases in human bone cells | Q28286213 | ||
| The molecular biology of androgenic 17 beta-hydroxysteroid dehydrogenases | Q28294591 | ||
| The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology | Q28303450 | ||
| New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays | Q29615588 | ||
| Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database | Q30494222 | ||
| Conformer generation with OMEGA: learning from the data set and the analysis of failures | Q30574063 | ||
| Effect of 17beta-hydroxysteroid dehydrogenase type 2 inhibitor on bone strength in ovariectomized cynomolgus monkeys. | Q30847970 | ||
| LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters | Q31143138 | ||
| A specific mechanism of nonspecific inhibition | Q31166009 | ||
| Sex steroids and bone | Q31817124 | ||
| E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. | Q33222654 | ||
| Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. | Q33233997 | ||
| Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries | Q33340787 | ||
| Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core | Q33510222 | ||
| The UV-filter benzophenone-1 inhibits 17beta-hydroxysteroid dehydrogenase type 3: Virtual screening as a strategy to identify potential endocrine disrupting chemicals. | Q33518126 | ||
| Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. | Q33843488 | ||
| Inhibition of 11 beta-hydroxysteroid dehydrogenase type 2 by dithiocarbamates | Q33967606 | ||
| Triazole ring-opening leads to the discovery of potent nonsteroidal 17β-hydroxysteroid dehydrogenase type 2 inhibitors | Q34061469 | ||
| A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. | Q34470260 | ||
| Efficient overlay of small organic molecules using 3D pharmacophores | Q34575180 | ||
| Predicting Cyclooxygenase Inhibition by Three-Dimensional Pharmacophoric Profiling. Part I: Model Generation, Validation and Applicability in Ethnopharmacology | Q36087257 | ||
| KNIME Workflow to Assess PAINS Filters in SMARTS Format. Comparison of RDKit and Indigo Cheminformatics Libraries | Q36088906 | ||
| Pharmacophore Model Refinement for 11β-Hydroxysteroid Dehydrogenase Inhibitors: Search for Modulators of Intracellular Glucocorticoid Concentrations. | Q36093176 | ||
| Sex steroids and bone health status in men. | Q36369307 | ||
| Osteoporosis: a still increasing prevalence | Q36385297 | ||
| SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation | Q36711822 | ||
| Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis | Q37621534 | ||
| Pharmacophore based drug design approach as a practical process in drug discovery | Q37725042 | ||
| Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy | Q37864207 | ||
| Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview | Q37912407 | ||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virtual screening | Q4112105 |
| P304 | page(s) | 5995-6007 | |
| P577 | publication date | 2014-07-10 | |
| P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
| P1476 | title | Ligand-based pharmacophore modeling and virtual screening for the discovery of novel 17β-hydroxysteroid dehydrogenase 2 inhibitors | |
| P478 | volume | 57 |
| Q41195167 | An Ab Initio Method for Designing Multi-Target Specific Pharmacophores using Complementary Interaction Field of Aspartic Proteases |
| Q45953663 | Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders. |
| Q35732424 | Discovery of new [Formula: see text] proteasome inhibitors using a knowledge-based computational screening approach |
| Q30959752 | Enrichment assessment of multiple virtual screening strategies for Toll-like receptor 8 agonists based on a maximal unbiased benchmarking data set. |
| Q36263268 | Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and posaconazole. |
| Q41660311 | Interference of Paraben Compounds with Estrogen Metabolism by Inhibition of 17β-Hydroxysteroid Dehydrogenases |
| Q35476224 | Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling |
| Q36268073 | Novel 11β-hydroxysteroid dehydrogenase 1 inhibitors reduce cortisol levels in keratinocytes and improve dermal collagen content in human ex vivo skin after exposure to cortisone and UV |
| Q90729095 | Osteoporosis: Mechanism, Molecular Target, and Current Status on Drug Development |
| Q34460371 | PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. |
| Q26772046 | Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts and Applications Exemplified on Hydroxysteroid Dehydrogenases |
| Q90430431 | Pharmmaker: Pharmacophore modeling and hit identification based on druggability simulations |
| Q30847424 | Potential Antiosteoporotic Natural Product Lead Compounds That Inhibit 17β-Hydroxysteroid Dehydrogenase Type 2. |
| Q50960965 | Structural insight into Mycobacterium tuberculosis maltosyl transferase inhibitors: pharmacophore-based virtual screening, docking, and molecular dynamics simulations. |
| Q34542053 | Structure-based discovery of potentially active semiochemicals for Cydia pomonella (L.). |
| Q34487793 | Type 2 17-β hydroxysteroid dehydrogenase as a novel target for the treatment of osteoporosis |
| Q36305610 | Virtual screening applications in short-chain dehydrogenase/reductase research. |
Search more.